A Critical Overview of the Biological Effects of Mitomycin C Application on the Cornea Following Refractive Surgery.
Esther Arranz-MarquezAndreas KatsanosVassilios P KozobolisAnastasios G P KonstasMiguel Angel TeusPublished in: Advances in therapy (2019)
During the last 2 decades, modifying the shape of the cornea by means of laser photoablation has emerged as a successful and popular treatment option for refractive errors. Corneal surface ablation techniques such as photorefractive keratectomy (PRK) and laser-assisted subepithelial keratomileusis (LASEK) offer good refractive results while having a minimal impact on corneal biomechanical stability. Past limitations of these techniques included the long-term regression of refractive outcome and a vigorous healing response that reduced corneal clarity in some patients (giving rise to what is clinically described as "haze"). Mitomycin C (MMC) was introduced as a healing modulator and applied on the corneal surface after refractive surgery to address these drawbacks. This article critically reviews the available evidence on the biological effects, safety, and clinical benefits of the off-label use of MMC in corneal refractive surgery.
Keyphrases
- cataract surgery
- minimally invasive
- coronary artery bypass
- optical coherence tomography
- wound healing
- end stage renal disease
- newly diagnosed
- chronic kidney disease
- physical activity
- ejection fraction
- prognostic factors
- emergency department
- patient safety
- high speed
- systematic review
- patient reported outcomes
- electronic health record
- percutaneous coronary intervention
- combination therapy